{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:57:00Z","timestamp":1780513020605,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100012353","name":"Deutschen Konsortium f\u00fcr Translationale Krebsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jmoldx.2022.04.001","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T17:05:27Z","timestamp":1656695127000},"page":"784-802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma\/Cell-Free DNA\u00a0Samples"],"prefix":"10.1016","volume":"24","author":[{"given":"Tamara V.","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Kock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0587-9742","authenticated-orcid":false,"given":"Gian","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2022.04.001_bib1","series-title":"WHO Classification of Tumours\u2014Female Genital Tumours","first-page":"252","article-title":"Tumours of the uterine corpus\u2014endometrioid carcinoma","volume":"volume 4","author":"Bosse","year":"2020"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jmoldx.2016.11.001","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology","volume":"19","author":"Sepulveda","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib5","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers","volume":"7","author":"Palmeri","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00428-017-2288-7","article-title":"Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics","volume":"472","author":"Hirsch","year":"2018","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/path.5048","article-title":"The value of cell-free DNA for molecular pathology","volume":"244","author":"Stewart","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib11","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.3390\/cancers12123804","article-title":"Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls","volume":"12","author":"Esposito Abate","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00428-017-2226-8","article-title":"EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial","volume":"471","author":"Fassunke","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib13","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib14","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","article-title":"The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.21037\/atm-20-7900","article-title":"Detection of ALK fusion transcripts in plasma of non-small cell lung cancer patients using a novel RT-PCR based assay","volume":"9","author":"Heeke","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib16","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1111\/cas.15084","article-title":"Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers","volume":"112","author":"Hasegawa","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib17","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jmoldx.2021.04.003","article-title":"Circulating plasma tumor DNA is superior to plasma tumor RNA detection in Ewing sarcoma patients: ptDNA and ptRNA in Ewing sarcoma","volume":"23","author":"Bodlak","year":"2021","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib20","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1038\/s41598-020-60375-x","article-title":"Comparison of target enrichment platforms for circulating tumor DNA detection","volume":"10","author":"Lam","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1186\/s12885-020-07445-5","article-title":"Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma","volume":"20","author":"Verma","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/diagnostics11081468","article-title":"Implementation of next generation sequencing-based liquid biopsy for clinical molecular diagnostics in non-small cell lung cancer (NSCLC) patients","volume":"11","author":"Zulato","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jmoldx.2017.06.004","article-title":"Comparison of blood collection tubes from three different manufacturers for the collection of cell-free DNA for liquid biopsy mutation testing","volume":"19","author":"Alidousty","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib25","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jmoldx.2017.05.008","article-title":"Molecular analysis of circulating cell-free DNA from lung cancer patients in routine laboratory practice: a cross-platform comparison of three different molecular methods for mutation detection","volume":"19","author":"Bartels","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/diagnostics10080521","article-title":"Next generation sequencing for gene fusion analysis in lung cancer: a literature review","volume":"10","author":"Bruno","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2019.06.004","article-title":"Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA","volume":"134","author":"Supplee","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2021.06.018","article-title":"Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions","volume":"159","author":"Mondaca","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib29","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jmoldx.2022.04.001_bib30","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jtho.2018.05.041","article-title":"Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples","volume":"13","author":"Davies","year":"2018","journal-title":"J Thorac Oncol"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157822001052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157822001052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:17:05Z","timestamp":1761502625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157822001052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1525157822001052"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2022.04.001","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma\/Cell-Free DNA\u00a0Samples","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2022.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}